SEC Tracker
Get the app

Akero Therapeutics AKRO

Andrew Cheng (AKRO) director John Doe purchased 10,000 shares of the company's stock for a total transaction value of $250,000 on Nov 13, 2025. This insider buying activity signals a bullish sentiment from company leadership and suggests they believe the stock is undervalued at current levels.

Andrew Cheng, insider filing for AKRO

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Akero Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. America Great Health AAGH
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.